Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Xencor, Inc.
Incyte Corporation
Duke University
Lytix Biopharma AS
National Cancer Institute (NCI)